文献詳細
特集 腎移植臨床の進歩―集学的治療における泌尿器科医の役割を再考する
〈腎移植後の内科的治療〉
文献概要
▶ポイント
・腎移植においては,拒絶反応・感染・免疫抑制薬など契機にTMAが発症することがある.
・そのなかには病態が急激かつ深刻である症例もあり,早期診断・早期治療介入を行わなければ,移植腎喪失や高度移植腎障害を引き起こす可能性がある.
・初期治療に不応な場合は,腎移植後の二次性TMAであっても,症例によっては適正にaHUSと診断し,エクリズマブ投与も含めた集学的治療が必要である.
・腎移植においては,拒絶反応・感染・免疫抑制薬など契機にTMAが発症することがある.
・そのなかには病態が急激かつ深刻である症例もあり,早期診断・早期治療介入を行わなければ,移植腎喪失や高度移植腎障害を引き起こす可能性がある.
・初期治療に不応な場合は,腎移植後の二次性TMAであっても,症例によっては適正にaHUSと診断し,エクリズマブ投与も含めた集学的治療が必要である.
参考文献
1) 非典型溶血性尿毒症症候群診断基準改定委員会, 日本腎臓学会, 日本小児科学会 (編) : 非典型溶血性尿毒症症候群 (aHUS) 診療ガイド2015 https://cdn.jsn.or.jp/guideline/pdf/ahus_2016-2.pdf
2) Tsai HM : A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome. Transfus Med Rev 28 : 187-197, 2014
3) Laurence J : Atypical hemolytic uremic syndrome (aHUS) : making the diagnosis. Clin Adv Hematol Oncol 10 : 1-12, 2012
4) Laurence J, Haller H, Mannucci PM, et al : Atypical hemolytic uremic syndrome (aHUS) : essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol 14 (Suppl 11) : 2-15, 2016
5) Noris M, Caprioli J, Bresin E, et al : Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5 : 1844-1859, 2010
6) Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al : Genetics and outcome of atypical hemolytic uremic syndrome : a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8 : 554-562, 2013
7) Loirat C, Fakhouri F, Ariceta G, et al : An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31 : 15-39, 2016
8) Cataland SR and Wu HM : How I treat : the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood 123 : 2478-2484, 2014
9) Goodship TH, Cook HT, Fakhouri F, et al : Atypical hemolytic uremic syndrome and C3 glomerulopathy : conclusions from a “Kidney Disease : Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 91 : 539-551, 2017
10) Le Quintrec M, Zuber J, Moulin B, et al : Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 13 : 663-675, 2013
11) Zuber J, Le Quintrec M, Sberro-Soussan R, et al : New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 7 : 23-35, 2011
12) Noris M and Remuzzi G : Atypical hemolytic-uremic syndrome. N Engl J Med 361 : 1676-1687, 2009
13) Zuber J, Le Quintrec M, Morris H, et al : Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando) 27 : 117-125, 2013
14) Ponticelli C and Banfi G : Thrombotic microangiopathy after kidney transplantation. Transpl Int 19 : 789-794, 2006
15) Le Quintrec M, Lionet A, Kamar N, et al : Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 8 : 1694-1701, 2008
16) Ponticelli C : De novo thrombotic microangiopathy. An underrated complication of renal transplantation. Clin Nephrol 67 : 335-340, 2007
17) Zuber J, Le Quintrec M, Krid S, et al : Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 12 : 3337-3354, 2012
18) Nürnberger J, Philipp T, Witzke O, et al : Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 360 : 542-544, 2009
19) Garg N, Rennke HG, Pavlakis M, et al : De novo thrombotic microangiopathy after kidney transplantation. Transplant Rev (Orlando) 32 : 58-68, 2018
20) Okumi M, Omoto K, Unagami K, et al : Eculizumab for the treatment of atypical hemolytic uremic syndrome recurrence after kidney transplantation associated with complement factor H mutations : a case report with a 5-year follow-up. Int Urol Nephrol 48 : 817-818, 2016
21) Ardissino G, Testa S, Possenti I, et al : Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome : a report of 10 cases. Am J Kidney Dis 64 : 633-637, 2014
22) Ardissino G, Possenti I and Tel F : In reply to ‘discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome’. Am J Kidney Dis 65 : 342-343, 2015
23) Ikeda T, Okumi M, Unagami K, et al : Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab. Nephrology (Carlton) 21 (Suppl 1) : 35-40, 2016
24) Rathbone J, Kaltenthaler E, Richards A, et al : A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open 3 : e003573, 2013
25) Campistol JM, Arias M, Ariceta G, et al : An update for atypical haemolytic uraemic syndrome : diagnosis and treatment. A consensus document. Nefrologia 33 : 27-45, 2013
26) Licht C, Greenbaum LA, Muus P, et al : Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87 : 1061-1073, 2015
掲載誌情報